Aquestive Therapeutics, Inc. (AQST)
$
3.16
-0.08 (-2.53%)
Key metrics
Financial statements
Free cash flow per share
-0.4607
Market cap
313.8 Million
Price to sales ratio
7.2311
Debt to equity
-31.3609
Current ratio
5.9307
Income quality
0.7314
Average inventory
8 Million
ROE
1.3950
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aquestive Therapeutics, Inc. is a pharmaceutical company that specializes in identifying, developing, and commercializing innovative products to meet unmet medical needs both in the United States and internationally. The company has seen an interest income of $3,437,000.00 showcasing its financial investments. Its total costs and expenses amount to $88,332,000.00 reflecting the overall spending while the cost of revenue is $17,872,000.00 which highlights its production and operational expenses. Additionally, the company reported selling, general, and administrative expenses of $50,180,000.00 indicating its operational overhead costs. The weighted average number of diluted shares outstanding is $86,726,211.00 revealing potential dilution effects on shareholders. Among its marketed products are Sympazan, a clobazam treatment for Lennox-Gastaut syndrome, and Suboxone, a sublingual film for opioid dependence. Other products include Zuplenz, designed for nausea and vomiting related to chemotherapy, and Azstarys, a once-daily treatment for ADHD. The company's proprietary pipeline features Libervant, a buccal formulation of diazepam for seizures, and Exservan, a film formulation of riluzole for ALS. Additionally, it is developing AQST-108 and AQST-305, both sublingual film formulations targeting various health conditions, and KYNMOBI for Parkinson’s disease management. The stock is affordable at $5.67 making it suitable for budget-conscious investors. With a high average trading volume of 3,881,316.00 the stock indicates strong liquidity, attracting interest from various traders. Currently, the company's market capitalization stands at $313,808,970.00 classifying it as a small-cap player within the market. As a key player in the Drug Manufacturers - Specialty & Generic industry, Aquestive Therapeutics contributes significantly to the overall market landscape while driving innovation and growth within the Healthcare sector. This dynamic positioning underscores the company's commitment to addressing critical health challenges and expanding its presence in the pharmaceutical market.
Is Aquestive Therapeutics, Inc. (AQST) a good investment?
Investing in Aquestive Therapeutics, Inc. (AQST) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Aquestive Therapeutics, Inc. (AQST)'s stock forecast?
Analysts predict Aquestive Therapeutics, Inc. stock to fluctuate between $2.12 (low) and $7.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aquestive Therapeutics, Inc.'s market capitalization?
As of 2026-01-30, Aquestive Therapeutics, Inc.'s market cap is $313,808,970, based on 99,306,636 outstanding shares.
How does Aquestive Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Aquestive Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aquestive Therapeutics, Inc. (AQST) stock?
To buy Aquestive Therapeutics, Inc. (AQST) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AQST. Place an order (Market, Limit, etc.).
What is the best time to invest in Aquestive Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Aquestive Therapeutics, Inc. perform in the last earnings report?
Revenue: $57,561,000 | EPS: -$0.51 | Growth: 292.31%.
Where can I find Aquestive Therapeutics, Inc.'s investor relations reports?
Visit https://www.aquestive.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aquestive Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Aquestive Therapeutics, Inc. stock?
All-time high: $7.55 (2025-10-20) | All-time low: $0.62 (2022-07-01).
What are the key trends affecting Aquestive Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).
newsfilecorp.com
New York, New York--(Newsfile Corp. - January 26, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. ("Aquestive Therapeutics, Inc.") (NASDAQ: AQST) concerning potential violations of the federal securities laws. What Happened?
prnewswire.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Jan. 25, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).
newsfilecorp.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 21, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).
globenewswire.com
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aquestive (AQST) To Contact Him Directly To Discuss Their Options
globenewswire.com
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
newsfilecorp.com
New York, New York--(Newsfile Corp. - January 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive Therapeutics, Inc.") concerning potential violations of the federal securities laws. What Happened?
prnewswire.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Jan. 17, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).
zacks.com
Aquestive Therapeutics (AQST) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
newsfilecorp.com
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aquestive Therapeutics, Inc. ("Aquestive Therapeutics, Inc.") (NASDAQ: AQST) concerning potential violations of the federal securities laws. What Happened?
See all news
